Purpose: Sorafenib is a potent kinase inhibitor. The purpose of this study was to discover genetic determinants of survival in metastatic renal cell carcinoma (mRCC) patients treated with sorafenib.
Introduction
Sorafenib tosylate (sorafenib, Nexavar®) is a vascular endothelial growth factor (VEGF)pathway inhibitor approved by the U.S. FDA for the treatment of advanced and metastatic renal cell carcinoma (mRCC), unresectable hepatocellular carcinoma, radioactive iodine-refractory differentiated thyroid carcinoma, and is becoming increasingly utilized off-label for FLT3mutated acute myeloid leukemia. Sorafenib is a potent inhibitor of VEGFR-2 and VEGFR-3, PDGFR-β, FLT-3, c-KIT, RAF-1, and BRAF (1) .
The phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) was a double-blind, randomized, placebo-controlled, multicenter study of 903 mRCC patients who had failed previous cytokine therapy (2) . Based upon results from TARGET and a previous phase II study, the U.S. FDA approved use of sorafenib for the treatment of mRCC (2, 3) . In mRCC, sorafenib is primarily used after progression on first-line therapy (4) .
Clear cell RCC is a malignancy characterized by high vascularization, resulting from molecular mechanisms that abrogate the activity of the VHL tumor suppressor gene (5, 6) .
Sorafenib affects tumor vascular endothelium, the tumor microenvironment, and the host vascular endothelium and pericytes (7, 8) . Because RCC is dependent on angiogenesis, the VEGF pathway is a viable target for drug therapy (9) , and sorafenib has been shown to inhibit angiogenic targets in multiple RCC models (9, 10) . As angiogenesis is primarily a host-mediated process (11) , germline variants that regulate angiogenic processes are likely to be associated with both disease progression and sorafenib efficacy.
Clinically, response to sorafenib is highly variable (2, 3, 12) , and molecular mechanisms underlying the interpatient variability in sorafenib efficacy have yet to be elucidated. While the armamentarium of treatment for mRCC has been expanded over the past decade, there is still uncertainty concerning selection and sequencing of these agents, particularly after patients progress on first-line therapy. Moreover, there is a dearth of validated molecular biomarkers to help inform clinicians about disease progression and drug efficacy.
Clinical studies using genetic analyses are ideal to select novel molecular candidates for testing in experimental models. Through this translational approach in reverse, novel mechanistic hypotheses can be produced to advance the field of precision oncology. In this study, 11, 117 germline DNA variants in 56 genes were tested for association with overall survival (OS) in 295 mRCC patients from the TARGET study. For variants associated with OS, we employed a series of functional experiments to determine novel mechanism by which DNA variation in angiogenesis genes might affect the biology of RCC and the efficacy of sorafenib.
Results
A total of 11,117 germline variants were tested for association with OS in 295 patients, and a flow diagram of patients and variants is shown in Supplementary Figure SF1 . The clinical characteristics of patients are shown in Table 1 . Using both P<0.05 and false discovery rate (FDR) q<0.10 as the threshold for statistical significance, seven variants were associated with OS ( Table 2 ). Because the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk score (P=0.05) and the number of metastatic sites (P=0.001) were associated with OS, they were included in the multivariate model testing the association between variants and OS.
Variants associated with OS in the sorafenib arm
Three variants located in genes were associated with OS ( Figure 1A- without the ATG insertion. None of the significant associations in the sorafenib arm were also significant in both arms combined. No significant associations were found in the placebo arm.
Variants associated with OS in both arms combined
Two variants located in genes were associated with OS ( Figure 1D -E). FLT4 rs307826 (A>G, HR=13.8; 95% CI, 3.0-62.6; P=1.2x10 -4 ) and VEGFA rs3024987 (C>T, HR=3.0; 95% CI, 1.7-5.4; P=8.3x10 -5 ) were associated with shorter OS. The mean OS was 194 (51-334) days for FLT4 rs307826 GG patients versus 394 (34-497) days for AA/AG patients; and 348 days for VEGFA rs3024987 CT patients versus 403 (34-409) days for CC patients (no TT genotypes were found). Neither of the significant associations in both arms combined were significant either in the sorafenib arm only or the placebo arm only.
Variants associated with progression-free survival (PFS)
As an exploratory analysis, variants that were significantly associated with OS (Table 2, Figure 1A -E) were also tested for their association with PFS (Supplementary Figure SF2 ).
VEGFA rs1885657 (HR=4.00, 95% CI 1.57-10.21; P=0.004), rs6719561 (3' of UGT1A9, HR=1.94, CI 1.00-3.76; P=0.05), WWOX rs8047917 (HR=1.77, CI 1.03-3.04; P=0.04), and FLT4 rs307826 (HR=2.92, CI 1. 19-7.19 ; P=0.019) were associated with PFS. However, ITGAV rs3816375, NRP1 rs200809375, and VEGFA rs3024987 were not associated with PFS (P>0.05).
FLT4 rs307826 (A>G, T494A) increases VEGFR-3 phosphorylation
FLT4 rs307826 is an A>G change that leads to a T494A amino acid substitution in VEGFR-3. FLT4 rs307826 GG was associated with shorter OS in both arms combined ( Figure   1D ). We tested the hypothesis that T494A might affect the function of VEGFR-3. In transfected HUVECs, T494A leads to increased phosphorylation of the fully-processed (190 kDa band) and the proteolytically-processed C-terminal (125 kDa band) forms of VEGFR-3 (13) , as compared to wild-type (WT) VEGFR-3. This effect was potentiated by VEGF-C stimulation (Figure 2A ), and was confirmed in independent experiments (Supplementary Figure SF3 ).
FLT4 rs307826 (A>G, T494A) increases rates of VEGFR-3 processing
To test the effect of T494A on VEGFR-3 post-translational processing, a pulse chase experiment was conducted in HUVECs. At both the 1 h and 2 h pulse chase time points, there is a clear decrease in mature VEGFR-3 (190 kDa band) for cells with T494A ( Figure 2B ).
Increased VEGFR-3 125 kDa to 170 kDa ratios were observed in cells with T494A compared to WT cells, with and without VEGF-C stimulation (P<0.01) ( Figure 2C ).
FLT4 rs307826 (A>G, T494A) does not affect VEGFR-3 O-glycosylation
Bioinformatic analyses predicted that 494A could be a potent site of O-ß-GlcNAc attachment ( Supplementary Figure xx) . However, in either HeLa cells or HUVECs, T494A showed all three VEGFR-3 polypeptide bands, indicating normal glycosylation and proteolytic processing (Supplementary Figure SF4 ).
FLT4 rs307826 (A>G, T494A) reduces sorafenib cytotoxicity
Based on the association between FLT4 rs307826 (A>G) and OS ( Figure 1D ) and results from the VEGFR-3 phosphorylation experiments, we tested the hypothesis that rs307826 might influence the cytotoxicity of sorafenib. In HEK293 cells with and without VEGF-C stimulation, VEGF-C-stimulated cells with the G allele were more resistant to sorafenib than cells with the A allele (mean sorafenib IC50 7.67 versus 2.02 µM, respectively; P<0.0001) ( Figure 3 ). In the absence of VEGF-C stimulation, cells with the G allele were also more resistant than cells with the A allele (mean IC50 15.45 versus 7.58 µM, respectively; P<0.0001).
Intronic variants associated with OS affect transcriptional activity in luciferase assays
With the exception of FLT4 rs307826, all other gene variants associated with shorter OS (Table 2 ) are intronic. Because they are of unknown significance, we tested their effect on transcriptional regulation using luciferase assays in human endothelial (LPECs, TIME) and RCC (Caki-1) cells.
VEGFA rs1885657 C increased luciferase activity by an average of 48% in LPECs (P=0.0116), 57% in TIME cells (P<0.0001), and 30% in Caki-1 cells (P=0.0166), when compared to the reference T allele. rs58159269 C and rs943070 G also increased luciferase activity. The "triple variant" construct (rs1885657 C/rs58159269 C/rs943070 G) had the greatest increase in luciferase activity (70-99%) in all cell lines (P<0.0001) ( Figure 4A ). VEGFA rs3024987 T increased luciferase activity in Caki-1 cells (34%, P=0.0032), TIME cells (38%, P=0.0002), and LPECs (32%, P=0.0001), when compared to the reference C allele ( Figure 4B ).
WWOX rs8047917 A increased luciferase activity in TIME cells (63%, P=0.0174), and
Caki-1 cells (40%, P<0.0001), but not LPECs, when compared to the reference T allele. The "triple variant" construct (rs77533819 C/rs8047917 A/rs7190035 C) had the greatest increase in luciferase activity (64-101%) in all cell lines (P<0.0001) ( Figure 4C ).
ITGAV rs381637 G increased luciferase activity in Caki-1 cells (57%, P<0.0001), TIME cells (51%, P<0.0001), and LPECs (27%, P=0.005), when compared to the reference C allele ( Figure 4D ).
VEGFA rs58159269 (T>C) increases endothelial cell proliferation
Out of the intronic variants increasing luciferase activity ( Figure 4A -D), we tested the effect of VEGFA rs58159269 in angiogenesis assays. Among the three VEGFA variants ( Figure   4A ), rs58159269 had the strongest luciferase activity in all three cell lines. VEGFA rs58159269 is in complete LD (r 2 1.0) with rs1885657, the VEGFA variant associated with shorter OS ( Figure 1A ). Hence, we tested the effect of rs58159269 on endothelial cell proliferation. In isogenic TIME cells transfected with rs58159269 C, endothelial cell proliferation was significantly greater than in cells with the T allele (176±11 versus 103±6 viable cells at 72 h, P<0.0001; Figure 5A ).
VEGFA rs58159269 (T>C) reduces sorafenib cytotoxicity
Because endothelial cells with rs58159269 C were characterized by increased proliferation, we tested whether increased proliferation would result in reduced cytoxicity of sorafenib. In the same isogenic TIME cells used above, cells with either the T or C allele were responsive to sorafenib. However, the IC50 of rs58159269 C cells was nearly double than the IC50 of cells with the T allele (IC50 6.43 versus 3.50 µM, Figure 5B ).
VEGFA rs58159269 (T>C) increases endothelial cell tube formation
Because endothelial cell proliferation was increased by rs58159269 C, we tested the hypothesis that rs58159269 C would affect endothelial tube formation. Using the same isogenic TIME cells, endothelial tube formation assays showed significantly increased branch points for cells with the C allele when compared to those with the T allele (219.50±27.21 versus 34.35±5.21 branch points, respectively, P<0.0001; Figure 5C ).
Discussion
This study represents the most comprehensive genetic analysis of sorafenib outcome in any tumor type. The most compelling discovery of this study is the clinical identification and subsequent experimental validation of FLT4 rs307826 as a negative determinant of OS. Patients with the FLT4 rs307826 GG genotype experienced significantly shorter OS than AA/AG patients in both arms combined ( Figure 1D ). FLT4 encodes VEGFR-3, a transmembrane kinase receptor that is a target of sorafenib, mediating lymphangiogenesis and playing a crucial role in vasculature growth and remodeling (14) (15) (16) . Inhibition of VEGFR-3 can suppress vascular network formation (17) , and preclinical models have shown that VEGFR-3 blockade can inhibit lymphatic metastasis (18) .
FLT4 rs307826 (A>G) results in a missense variant that causes a threonine to alanine amino acid substitution (T494A). Our experimental results clearly indicate that T494A not only increases VEGFR-3 phosphorylation, but also VEGFR-3 signaling and membrane trafficking. Figure SF5) (19) , which contributes important homotypic interactions that are essential for VEGFR-3 dimerization and activation.
In our mechanistic experiments, T494A increased basal and VEGF-C-stimulated phosphorylation of VEGFR-3 (Figure 2A ), suggesting its importance as a driver of increased signaling. Increased phosphorylation could result in a more aggressive form of RCC, possibly due to more rapid metastatic spread secondary to increased lymphangiogenesis. T494A may also increase membrane trafficking of VEGFR-3. Pulse chase experiments revealed increased formation of the proteolytically-processed C-terminal fragment (i.e., increased 125:170 kDa band ratio), as well as increased formation of mature VEGFR-3 (i.e., presence of 190 kDa band) in cells with T494A ( Figure 2B -C). Faster decrease of ???? VEGFR-3 with T494A could indicate more rapid endocytosis and degradation. One plausible mechanistic hypothesis could be that T494A renders VEGFR-3 more susceptible to internalization and signaling activation (21, 22) . VEGFR-3 internalization is crucial to the activation of downstream signaling pathways (21) .
Evidence from our clinical and experimental results indicate that, in mRCC patients with T494A, increased VEGFR-3 phosphorylation and membrane trafficking lead to potentiated VEGFR-3 signaling, resulting in a more aggressive tumor due to increased angiogenesis and lymphoangiogenesis. These patients had shorter OS and PFS. Similar to our study, patients with T494A had shorter survival in other studies in mRCC patients treated with angiogenesis inhibitors (sunitinib and pazopanib) (23) (24) (25) . These clinical studies, now including ours, are all consistent for FLT4 rs307826 T494A to be a negative determinant of survival in mRCC. One limitation is that these studies cannot establish whether this effect is prognostic and/or predictive of the efficacy of angiogenesis inhibitors. Our experimental studies seem to suggest that T494A could also result into resistance to sorafenib cytotoxicity (Figure 3) , and the effect of T494A on the cytoxicity of other angiogenesis inhibitors should be tested in the future.
In addition to FLT4, this paper also provides evidence for VEGFA as a genetic determinant of survival in mRCC. VEGFA encodes for VEGF-A, the most potent proangiogenic agent (26) . In mRCC, increased circulating VEGF-A levels were shown to be negatively prognostic (12, 27) . In the present study, two intronic variants in VEGFA were associated with shorter OS: rs1885657 in sorafenib-treated patients ( Figure 1A ) and rs3024987 in both arms ( Figure 1E ). For both rs1885657 and rs3024987, the luciferase assays in endothelial and RCC cell lines ( Figure 4A-B ) resulted in increased transcriptional activity of the alleles associated with shorter OS. Although luciferase assays test the activity of a construct and not of the whole gene, these results are suggestive of increased regulatory activity of these variants on VEGFA expression. This effect might confer increased angiogenic potential to the tumor. We tested this hypothesis by using angiogenesis models based upon isogenic endothelial cells created by gene editing. Instead of rs1885657, for these assays we used rs58159269 because of its stronger effect on luciferase assays ( Figure 4A ) and complete LD with rs1885657. Cell proliferation and endothelial tube formation were potentiated by rs58159269, resulting in reduced cytotoxicity of sorafenib ( Figure 5A-B) . A tube formation assay confirmed that the increased effect on endothelial cell proliferation resulted into potentiated angiogenesis ( Figure   5C ). These experimental results point towards a mechanism where tumors in patients with VEGFA rs1885657 might be more resistant to sorafenib due to a more aggressive angiogenic phenotype. Because VEGFA rs1885657 conferred resistance also in cells treated with sunitinib ( Supplementary Figure xx) , the clinical effects of VEGFA rs1885657 should be also tested in mRCC patients treated with other angiogenesis inhibitors.
Additional potentially intriguing associations include ITGAV rs3816375 and WWOX rs8047917, both intronic variants associated with shorter OS in sorafenib-treated patients. ITGAV codes the αv integrin subunit, which can heterodimerize with multiple β subunits. Integrin αvβ3 is upregulated in both tumor and endothelial cells, and has been shown to regulate angiogenesis (32, 33) . The increased luciferase activity of ITGAV rs3816375 G ( Figure 4D) generates the hypothesis that rs3816375 could be contributing to ITGAV overexpression, increased angiogenesis, and reduced efficacy of sorafenib. For WWOX rs8047917, the increased luciferase assay appears to be discordant with the well-described tumor suppressor properties of WWOX (34) , and additional experimental evaluation is needed.
The evidence from the clinical effects on shorter OS, combined with a mechanistic demonstration of their biological and pharmacological effects, proposes FLT4 rs307826 and VEGFA rs1885657 as two novel biomarkers for mRCC and sorafenib treatment. Their identification and functional validation is an important step towards personalization of sorafenib treatment in mRCC, and these novel gene variants should be evaluated in further clinical studies.
Patients, materials and methods

TARGET study and patient characteristics
TARGET was a double-blind, randomized, placebo-controlled phase III trial of patients with unresectable RCC or mRCC who had received prior cytokine therapy (n=903) (2, 12) .
Patients were randomized 1:1 to either 400 mg sorafenib orally twice daily or placebo. Patients remained on study until disease progression, discontinuation due to intolerable toxicity, or death.
The primary endpoint was OS, defined as the time from the date of randomization until the date of death, and it was also used as the primary endpoint for this genetic study. To avoid the confounding effect of crossover of patients from the placebo arm to the sorafenib arm, the OS data used in this study were recorded before patient crossover. PFS was measured from the date of randomization until the date of progression, as defined by the trial protocol (2) . The clinical characteristics and median OS of the 295 genotyped patients were comparable to those of the entire TARGET population ( Table 1 ). All patients provided written informed consent to participate in this genetic analysis, approved by the institutional review board at each center.
Genotyping of gene variants
A total of 56 genes were selected for genotyping. The biological function of each gene is described in Supplementary Table ST1 . Selection criteria for single-nucleotide polymorphisms (SNPs) to be genotyped are described in the Supplementary Methods. Germline DNA was extracted from peripheral blood (FlexiGene DNA kit, Qiagen) and 1,536 SNPs were genotyped using the Illumina GoldenGate assay. Genotypes were determined using Illumina GenomeStudio software v2011. Variants were excluded if the genotype call rate was <97.5%, the minor allele frequency (MAF) was <1%, or if they deviated from Hardy-Weinberg equilibrium (HWE; P<0.0001). GenTrain scores were derived from Illumina GenomeStudio scatter plots to measure variant detection reliability based on genotypic clustering distributions (36) , and only SNPs with GenTrain scores >0.4 were included. Additional variants were obtained through imputation using Impute2 version 2.30 (37) . Overall, 11,117 variants were included in the final analyses (Supplementary Figure SF1 ). Imputation methods are included in the Supplementary Methods.
Statistical analyses
The primary objective was to identify gene variants associated with OS. Univariate log rank tests were conducted to test each variant-OS association in the sorafenib arm, the placebo arm, and both arms combined. To determine if any clinical or demographic characteristic needed to be modeled along with the genetic variants, likelihood ratio tests were performed to look for associations between OS and each of the following factors: country of origin, gender, age, Eastern Cooperative Oncology Group performance status, time since RCC diagnosis, previous systemic treatment with IL-2 or INF, MSKCC prognostic risk score, number of metastatic sites, and evidence of liver or lung metastases. Cox proportional hazards regression included both genetic variants identified by the log rank tests described above and significant clinical covariates (P≤0.05). Additive, dominant, or recessive models were used. FDR q-values were calculated to account for multiple testing (38) . FDR was employed in lieu of correcting the family-wise error rate (i.e., Bonferroni correction) to better account for the correlation among tests resulting from the linkage disequilibrium (LD) among variants. Variant-OS associations were regarded statistically significant if P<0.05 and q<0.10. The restricted mean OS was used to report the OS for each genotype, and was selected in lieu of median OS because the median was undefined for many variants, either because more than half of the patients were alive at the date of the final event, or the last event was censored (39) . 
VEGFR-3 o-glycosylation and phosphorylation assays
The human VEGFR-3 amino acid sequence was analyzed using YinOYang software (40) for potential O-glycosylation by assessing the potent O-ß-GlcNAc attachments. The effect of T494A on VEGFR-3 expression was tested using an SDS-PAGE gel by immunoprecipitation and western blotting. VEGFR-3 WT and T494A were expressed in HeLa cells and HUVECs upon retroviral transfection. The constructs were Strep-tagged to allow separation from the endogenous VEGFR-3 in the HUVECs. Streptactin-sepharose precipitated samples were run on an 8% SDS-PAGE and western blotted with anti-VEGFR-3 antibodies (AF743, R&D Systems) as previously reported. (19, 20) The effect of T494A on VEGFR-3 phosphorylation was investigated in VEGF-Cstimulated HUVECs. After a 2 h starvation, 494T and 494A retrovirally-transfected cells were stimulated with mature VEGF-C (ΔNΔC-VEGF-C) at a final concentration of 50 ng/mL for 20 min. Strep-tagged VEGFR-3 proteins in the lysates were precipitaed with streptactin sepharose.
They were then loaded onto an 8% SDS-PAGE gel and western blotted for phospho-tyrosines (4G10) and total VEGFR-3.
VEGFR-3 pulse-chase experiments to evaluate VEGFR-3 processing
VEGFR-3 transfected HUVECs were starved for 2 h in met-/cys-deficient DMEM without serum, after which 1 mL of labelling medium (met-/cys-deficient DMEM supplemented with 20 µL EasyTag EXPRESS 35S/ml) was added for 2 h. Cells were washed with warm PBS and 5 mL of chase medium was added (DMEM 10% FCS+1 mM cold L-methionine+2 mM cold L-cysteine). At the indicated time points, cell plates were place on ice, the medium was removed, and the cells washed with PBS before being lysed. Analysis was performed by precipitating Strep-tagged VEGFR-3 from the samples with streptactin sepharose. The precipitated samples were resolved on a reducing SDS-PAGE, and signals captured with a phosphoimager plate and a Typhoon scanner. The 125 kDa gel band gel appears at 130 kDa band due to the double strep tag.
A Student's t test was used to compare means from cells with the WT versus T494A cells (n=3).
Viability assays in sorafenib-treated cells transfected with FLT4 rs307826 (A>G, T494A)
FLT4 cDNA was introduced in a pCMV6-XL5 expression vector, and the variant rs307826 G allele was introduced using site-directed mutagenesis. Sanger sequencing was µM (38, 39) ). After 72 h, AlamarBlue® was used to assess cell viability. Three independent experiments in triplicate were performed. IC50 values were obtained using a four-parameter nonlinear regression model that was top constrained to 1.0 to assess log10 sorafenib concentration versus average percent viability. Two-sided t-tests were used to assess differences between IC50 values.
Luciferase activity assays of intronic variants
All constructs containing variants in VEGFA, ITGAV, and WWOX were synthesized and inserted into the pGL4.26 [luc2/minP/Hygro] plasmid upstream of its minimal promoter. Sitedirected mutagenesis was used to introduce all variants. Sanger sequencing was used to confirm mutagenesis. Caki-1 cells were transfected using Lipofectamine® LTX and a Renilla HSV-TK plasmid control reporter. TIME cells were transfected using TransIT-2020 transfection reagent and a Renilla SV40 plasmid control reporter. LPEC cells were transfected using magnetofection with CombiMag magnetic nanoparticles, TransIT-2020, and Renilla SV40. Cells were lysed 40 h after transfection and luciferase assays were performed. Four independent experiments were conducted in triplicate for each construct. Luciferase activity was calculated as the Firefly to Renilla luciferase ratio, normalized to the empty vector. A one-way ANOVA followed by pairwise comparisons was used, with Dunnett's correction for multiple testing.
Creation of isogenic cell lines of VEGFA rs58159269 (T>C)
A Direct Cell Proliferation Assay (Life Technologies). Images were acquired using the EVOS FLc microscope (Life Technologies) using a 10x objective and counts were accomplished with FIJI particle analyzer. A two-tailed, unpaired t-test was used to analyze differences in cell proliferation and cytotoxicity between TT and CC cells.
Endothelial cell tube formation assays in isogenic cell lines
TT and CC isogenic endothelial cell lines were plated, grown and quiesced, as described above for proliferation studies. Matrigel (EMD Millipore) was set into 96 well plates according to the manufactures instructions. Cell viability was assessed using Trypan Blue (Bio-Rad). Cells were then added to each well at a final concentration of 50,000 cells/150 µl in EGM-2 MV media with 2.5% FBS. Cells were treated with sorafenib (0.1 µM, 1 µM, 10 µM). Untreated cells and cells with DMSO (final concentration 1:4000) were used as controls. Cells were then incubated for 4 h at 37 o C, 5% CO2, and 95% humidity. Images were acquired using the EVOS FLc microscope (Life Technologies) using a 4x objective, and number of branch points (nodes) was determined using FIJI angiogenesis analyzer. A two-tailed, unpaired t-test with Welch's 
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